Long-term Beta-Blockers Not Needed for Some After MI? Long-term Beta-Blockers Not Needed for Some After MI?
Beta-blocker treatment beyond 1 year after MI for patients without heart failure or left ventricular systolic dysfunction was not associated with improved cardiovascular outcomes in a new analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 3, 2023 Category: Consumer Health News Tags: Cardiology News Source Type: news
β-Blockers Seem Not to Reduce Risks More Than One Year After Heart Attack
WEDNESDAY, May 3, 2023 -- For patients with myocardial infarction (MI), beta-blocker (βB) treatment beyond one year after MI does not appear to reduce the risk for mortality or further MI, according to a study published online May 2 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2023 Category: Pharmaceuticals Source Type: news
Beta blockers may not be effective for everyone, surprising study suggests
A new study suggests that beta blockers might not be beneficial for all heart attack survivors. (Source: Daily Express - Health)
Source: Daily Express - Health - May 3, 2023 Category: Consumer Health News Source Type: news
Case Builds Against Beta-Blockers Beyond First Year After Heart Attack
(MedPage Today) -- The conventional wisdom of giving long-term beta-blockers for secondary prevention after myocardial infarction (MI), in the absence of another clinical indication, was questioned by a large cohort study from Sweden.
For survivors... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 3, 2023 Category: Cardiology Source Type: news
Beta-Blockers in AF -- Making Sense of Unsettling Results Beta-Blockers in AF -- Making Sense of Unsettling Results
Beta-blockers are commonly used to help control heart rate in patients with atrial fibrillation, but conflicting study results raises questions.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2023 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Researchers Are Getting Closer to Learning How to Treat and Prevent Long COVID
Three years into the COVID-19 pandemic, with millions of people around the world suffering from long-term complications of the virus, there is still no proven way to treat or prevent Long COVID—besides not getting infected in the first place.
Recently, however, there’s been reason for cautious optimism. Researchers have found promising (though preliminary) signs that certain drugs may reduce the risk of developing Long COVID, and possibly even ease symptoms among people who are already sick.
The latest hopeful news relates to metformin, an accessible and affordable drug that’s been U.S. Food and Drug Admi...
Source: TIME: Health - March 16, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
A clinical-epidemiological study on beta-blocker poisonings based on the type of drug overdose - Eizadi-Mood N, Adib M, Otroshi A, Dorooshi G, Meamar R.
BACKGROUND: Beta-blockers carry a high risk of potentially causing fatal poisoning if overdosed. We aimed to assess the clinical and epidemiological characteristics of patients with beta-blocker poisoning. METHODS: Patients were categorized based o... (Source: SafetyLit)
Source: SafetyLit - March 13, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
No Consistent Link Found Between β-Blockers, Psychiatric Outcomes
WEDNESDAY, March 1, 2023 -- There are no consistent links betweenβ-blockers and psychiatric outcomes, according to a study published online Jan. 31 in PLOS Medicine.
Yasmina Molero, Ph.D., from the Karolinska Institutet in Stockholm, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2023 Category: Pharmaceuticals Source Type: news
Accelerated Pacing a Possible Strategy for HF With Preserved EF? Accelerated Pacing a Possible Strategy for HF With Preserved EF?
A study challenges the dogma of beta-blockers for HF with preserved ejection fraction. For now, the strategy might only be for HFpEF patients already with pacemakers.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 2, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Major study suggests beta-blockers for heart health could reduce violent crime
In a study involving more than 1.4 million people, Swedish and British scientists uncovered an association between treatments with beta blockers and a reduction in violent crime. (Source: the Mail online | Health)
Source: the Mail online | Health - February 1, 2023 Category: Consumer Health News Source Type: news
Preop Beta-Blockers and Stroke in Major Abdominal Surgery Preop Beta-Blockers and Stroke in Major Abdominal Surgery
Perioperative beta-blockade is sometimes used to reduce the risk of major adverse cardiac events for patients undergoing major noncardiac surgery. Does this increase the risk of stroke?Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2023 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
Is This Primary Exertional Headache?
Discussion
Commonly occurring primary headaches include tension, cluster and migraine headaches. “Other primary headaches” are often situational. Patients can have more than 1 type of these “other” headaches along with more common headaches. Other primary headaches as a group tend to be self-limited with long remission periods. Some other primary headaches include:
Thunderclap headache
Explosive sudden onset with maximum intensity in less 1 minute and resolution within 5 minutes usually
43/100,000 persons in adults
Primary or secondary
Secondary causes include intracranial hemorrhage, stroke, thro...
Source: PediatricEducation.org - November 21, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
New Update Focuses on Acute Kidney Injury Management in Cirrhosis New Update Focuses on Acute Kidney Injury Management in Cirrhosis
Prevent volume loss, manage risk factors, hold beta blockers, and stop NSAIDs are among the key recommendations in a new update to prevent acute kidney injury in patients with cirrhosis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 27, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
' Amazing' Data for Cheap Beta-Blocker Gel for Diabetic Foot Ulcers'Amazing' Data for Cheap Beta-Blocker Gel for Diabetic Foot Ulcers
Esmolol, a widely available and cheap beta-blocker, shows statistically significant superiority over the standard of care for diabetic foot ulcers, according to new, ' potentially game-changing ' phase 3 data.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 21, 2022 Category: Dermatology Tags: Diabetes & Endocrinology News Source Type: news
